GreenState column blasts two-tier Schedule III plan as 'a scam'

A column, not a rule: what GreenState actually published

The Nov. 12 piece is an opinion column in GreenState's "Legalization Nation" series, not a regulatory action, and it doesn't report a new DEA decision.

The headline calls a two-tier Schedule III system "a scam." The signal available to CannIntel carries only that headline and a source line. It doesn't include the column's full text, its author's byline, or any new federal filing. We're reporting the argument as framed in the title and the policy context around it, and we aren't attributing specific claims to the author beyond what the headline states.

That distinction matters. Rescheduling debates generate a steady flow of commentary, and a column is a position, not a development.

What a two-tier Schedule III system means

The "two-tier" label describes a split in which medical marijuana, and products tied to FDA-style or physician-supervised pathways, would be treated differently from state-licensed adult-use sales.

Under the Controlled Substances Act, moving marijuana from Schedule I to Schedule III would acknowledge accepted medical use and a lower abuse potential. It wouldn't, by itself, legalize state adult-use markets. Schedule III substances still require DEA registration for manufacture and distribution, and they remain subject to federal prescription and production-quota rules.

A two-tier approach would draw a line inside that framework. One track would carry the regulatory standing and tax relief that come with a recognized medical product, while the other, covering recreational sales, could remain outside those protections even as the plant sits on a lower schedule. Critics of that design argue it would reward a small set of participants. The bulk of the legal market would be left in limbo.

The 280E question sits at the center

Section 280E of the Internal Revenue Code bars deductions for businesses trafficking in Schedule I and II substances, so the tax outcome depends on which operators a rescheduling rule actually reaches.

Moving marijuana to Schedule III would, on its face, take it out of 280E's reach. Operators have spent years paying effective tax rates that some MSOs have described as punishing, because they can't deduct ordinary operating costs. Relief from 280E is the single largest financial prize in rescheduling.

That's why the structure of any tiering carries so much weight. If only medical-track businesses qualify for Schedule III treatment, an adult-use operator could keep paying under the old rules. Some license holders would get tax relief and others, in the same state, wouldn't. That is the practical concern behind the column's blunt framing.

Where rescheduling stands in federal process

The Department of Justice and DEA have been working through the rescheduling process that began with a Health and Human Services recommendation to move marijuana to Schedule III.

The formal path runs through rulemaking and, if contested, an administrative hearing before a DEA administrative law judge. Each stage gives the agency openings to shape the final scope of the rule, including whether and how it distinguishes categories of marijuana products or users. Readers tracking the mechanics can find the running timeline on the CannIntel topic hub on DEA rescheduling.

No final rule that would create a formal two-tier structure is reflected in the signal we reviewed. The column responds to a design concept and to the way it has been discussed in the policy community. It isn't responding to a published regulation.

Who wins and who loses under a split

The distributional stakes are the real story: a medical-only Schedule III benefit would favor operators with pharmaceutical-grade compliance and could leave smaller adult-use licensees behind.

Large multistate operators with deep compliance budgets are best positioned to qualify for any DEA-registered or FDA-adjacent pathway. Small and mid-size operators in states such as California, Colorado, and Oregon, many already squeezed by price compression, would face a harder climb. They'd also stay exposed to 280E if the adult-use side were carved out.

That's a policy design question, not a foregone conclusion. Congress, not DEA alone, controls the tax code. Even a clean Schedule III rule wouldn't rewrite banking access or interstate commerce restrictions.

The column's core objection, as its headline frames it, is that a tiered system would present itself as reform while preserving the burdens that matter most to the state-legal adult-use market.

Why the framing resonates with operators

Operators have heard rescheduling pitched as a tax fix, and a tiered structure that excludes adult-use sales would deliver far less than that pitch implied.

The industry's lobbying posture has leaned heavily on 280E relief as the headline benefit. A rule that grants it selectively would be a harder sell to the licensees who funded much of the advocacy. The sentiment in a column like this is predictable. It isn't a surprise, and it won't be the last of its kind.

The more useful question for operators is what the DEA's proposed text actually says about scope. Commentary can flag a risk. Only the rule's language settles who is covered, and legal counsel at multistate operators are likely reading that text closely.

What to watch next

The signals that will resolve this debate are the text of any final DEA rule, any scheduled administrative hearing, and congressional movement on the tax code.

Three markers matter. First, whether DEA's published language defines marijuana by use category or applies Schedule III uniformly. Second, whether a hearing before an administrative law judge is scheduled and who is granted participant status. Third, whether lawmakers in the House or Senate advance standalone legislation addressing 280E independent of scheduling.

Until one of those lands, a column calling the design a scam is an argument about a structure that hasn't been formally adopted. The rule's text will tell you more than the commentary around it.